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Summary
Background The roll-out of antiretroviral therapy (ART) has changed contexts of HIV risk, but the influence on HIV 
incidence among young women is not clear. We aimed to summarise direct estimates of HIV incidence among 
adolescent girls and young women since ART and before large investments in targeted prevention for those in sub-
Saharan Africa.
Methods We did a systematic review and meta-analysis. We searched MEDLINE, Embase, Web of Science, Global 
Health, and CINAHL for studies reporting HIV incidence data from serological samples collected among females 
aged 15–24 years in ten countries (Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Tanzania, Uganda, 
Zambia, and Zimbabwe) that were selected for DREAMS investment in 2015. We only included articles published in 
English. Our main outcome was to summarise recent levels and trends in HIV incidence estimates collected between 
2005 and 2015, published or received from study authors, by age and sex, and pooled by region.
Findings 51 studies were identified from nine of the ten DREAMS countries; no eligible studies from Lesotho were 
identified. Directly observed HIV incidence rates were lowest among females aged 13–19 years in Kumi, Uganda 
(0∙38 cases per 100 person-years); and directly observed HIV incidence rates were highest in KwaZulu-Natal, South 
Africa (7∙79 per 100 person-years among females aged 15–19 years, and 8∙63 in those aged 20–24 years), among 
fishing communities in Uganda (12∙40 per 100 person-years in females aged 15–19 years and 4∙70 in those aged 
20–24 years), and among female sex workers aged 18–24 years in South Africa (13∙20 per 100 person-years) and 
Zimbabwe (10∙80). In pooled rates from the general population studies, the greatest sex differentials were in the 
youngest age groups—ie, females aged 15–19 years compared with male peers in both southern African (pooled 
relative risk 5∙94, 95% CI 3∙39–10∙44) and eastern African countries (3∙22, 1∙51–6∙87), and not significantly different 
among those aged 25–29 years in either region. Incidence often peaked earlier (during teenage years) among high-
risk groups compared with general populations. Since 2005, HIV incidence among adolescent girls and young 
women declined in Rakai (Uganda) and Manicaland (Zimbabwe), and also declined among female sex workers in 
Kenya, but not in the highest-risk communities in South Africa and Uganda.
Interpretation Few sources of direct estimates of HIV incidence exist in high-burden countries and trend analyses 
with disaggregated data for age and sex are rare but indicate recent declines among adolescent girls and 
young women. In some of the highest-risk settings, however, little evidence exists to suggest ART availability and 
other efforts slowed transmission by 2016. Despite wide geographical diversity in absolute levels of incidence in 
adolescent girls and young women, risk relative to males persisted in all settings, with the greatest sex differentials 
in the youngest age groups. To end new infections among the growing population of adolescents in 
sub-Saharan Africa, prevention programmes must address gender inequalities driving excessive risk among 
adolescent girls.
Funding This work was conducted as part of a planning grant funded by the Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Young people, and young women in particular, have been 
identified as a group at disproportional risk of HIV 
infection. Global estimates from 2015 indicate that young 
people represent 34% of all new HIV infections, with 
adolescent girls and young women accounting for most 
of those.1 The UNAIDS’ 2014 Gap Report highlights the 
particularly high burden of HIV among young women in 
sub-Saharan Africa, where 80% of all young women 
living with HIV infection reside.2
The high levels and unequal distribution of HIV 
infection among young people have prompted a focus on 
adolescents as a target population for HIV prevention. 
In December, 2014, for example, the US President’s 
Emergency Plan for AIDS Relief (PEPFAR) set bold and 
urgent HIV prevention and treatment targets, including 
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the reduction of HIV incidence among adolescent girls 
and young women by 40% within 2 years. The so-called 
DREAMS Partnership, led by PEPFAR, the Bill & Melinda 
Gates Foundation, and Girl Effect, seeks to achieve this 
reduction through scale-up of interventions targeting the 
root causes of vulnerability to HIV acquisition in 
adolescent girls and young women, including biological, 
behavioural, social, and structural sources. A core 
package of interventions aims to promote determined, 
resilient, empowered, AIDS-free, mentored, and safe 
adolescent girls and young women in ten sub-Saharan 
African countries (Kenya, Lesotho, Malawi, Mozambique, 
South Africa, Swaziland, Tanzania, Uganda, Zambia, and 
Zimbabwe) that together account for more than half of 
all new HIV infections globally in adolescent girls and 
young women.3,4
In another recent initiative—All In to End Adolescent 
AIDS—UNICEF and global partners aim to reduce new 
HIV infections among adolescents (10–19 years) by 
75% by 2020, and end the AIDS epidemic among 
adolescents by 2030. Decisions about such investments 
have been based largely on HIV prevalence data and 
modelled incidence estimates, which are more readily 
available than data from observed incidence. Although 
prevalent cases will often represent or proxy recent 
infection among young people, because of recent sexual 
debut, prevalence estimates will also include those 
infected vertically.5 The number of such children is 
unknown, but this number is often substantial and 
rising with increased survival because of scale-up of anti-
retroviral therapy (ART).
Directly observed estimates of HIV incidence can be 
more useful than prevalence data in identifying the timing 
of new infections, and consequently the windows of 
opportunity and the populations and places of highest 
risk, for maximum impact of prevention efforts. Incidence 
estimates can also reveal changes in HIV transmission 
over time, such as the past decade in which mass scale-up 
of ART and prevention of mother-to-child transmission 
changed the context of risk. As more sexual partners reach 
viral suppression, transmission and incidence should 
decline as ART coverage increases, and indeed, evidence 
is emerging of declining incidence at global, regional, and 
national levels.6 Yet, it is not clear whether new infections 
are slowing among young people in the highest prevalence 
settings. ART adherence among male sexual partners of 
adolescent girls and young women is not well known, and 
among young people themselves, uptake of HIV testing 
and coverage of ART are low and AIDS-related deaths 
remain high, relative to all other age groups.7,8 The most 
recent review of HIV incidence studies summarised 
estimates published through 2007 and identified scant 
Research in context
Evidence before this study
Young women have been identified as a population group 
at particular risk for HIV infection. Epidemiology reports of 
the UN Programme on HIV/AIDS, based on surveys and 
mathematical modelling of HIV prevalence data in 
high-burden countries, consistently show prevalence 
increasing quickly between the ages of 15 and 24 years, 
more steeply in women than in men. Declines in HIV 
incidence have been reported among adult populations in 
numerous settings since widespread roll-out of 
antiretroviral therapy (ART).
Added value of this study
Compiling direct estimates of HIV incidence among young 
people—from published studies and unpublished data—
has revealed a heterogeneous body of evidence to 
understand trends among young people since ART 
availability. In the decade following ART roll-out, we found 
indications that absolute levels of incidence among 
adolescent girls and young women had declined in Rakai 
(Uganda), Manicaland (Zimbabwe), and nationally in 
South Africa, but not yet in the highest-burden settings 
within South Africa—where rates among the general 
population of young women matched those among the 
highest-risk populations elsewhere, such as female sex 
workers in Zimbabwe and bar workers in Tanzania. Rates of 
HIV also did not decline among adolescent girls and young 
women in fishing communities in Uganda. Among 
high-risk groups, this review shows that incidence can peak 
at an earlier age than in general populations—risk is 
commonly higher among females aged 15–19 years than 
those aged 20–24 years in studies sampling sex workers, 
bar workers, or pregnant women. One analysis of time 
trends in incidence among a high-risk population—sex 
workers in Mombasa—showed benefits from ART coverage 
and other initiatives. Gender disparities in risk persisted 
since ART availability. HIV risk was higher among females 
aged 15–19 years than among male peers in all studies, 
settings, and timepoints; in pooled analyses, this increased 
up to six times higher for females in the southern African 
region and three times higher for females in eastern Africa.
Implications of all the available evidence
Our review shows emerging evidence for recent declines in 
HIV incidence among adolescent girls and young women 
but the availability of ART and other interventions might be 
insufficient or slow to halt HIV infections among young 
women in the highest risk groups and settings, or rectify the 
relative risk for female adolescents. The persistent gender 
and age factors that drive transmission dynamics must be 
directly addressed to accelerate declines and achieve 
epidemic control goals. Supporting young adult men 
through testing, prevention, and treatment cascades must 
be part of the solution.
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data from direct estimation of HIV incidence in high-
prevalence countries, with few estimates for young people 
specifically.9
In light of the aforementioned, we sought to identify 
more recent estimates of HIV incidence, for better 
understanding of adolescent girls’ and young women’s 
risk in the time since ART scale-up—considered the 
third phase of the global HIV pandemic10—and to help 
inform prevention efforts that target young people.
Methods
Search strategy and selection criteria
We did a systematic review and meta-analysis. We sought 
to summarise recent levels and trends in HIV incidence 
among adolescent girls and young women in the ten 
countries selected in 2015 for DREAMS investment: 
Kenya, Lesotho, Malawi, Mozambique, South Africa, 
Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe. 
Articles with HIV incidence estimates were identified 
through searches of databases for peer-reviewed published 
papers, and through contact with authors of eligible 
studies for data further disaggregated by age and sex.
Our inclusion criteria consisted of the following: time-
frame (HIV incidence estimates based on serological data 
collected from 2005 [a proxy for roll-out of ART and 
prevention of mother-to-child transmission] to 2015 [proxy 
baseline for DREAMS implementation, which began in 
2016]), location (study done in a DREAMS country), age 
(15–24 years included in the study sample), population 
(includes data for adolescent girls and young women 
[their male counterparts also considered]), study design 
(studies with collection of serological samples, either with 
repeat HIV testing through prospective designs or use of 
assays for estimates of recent HIV infection; incidence 
estimates based on mathematical modelling were not 
included), and outcome of interest (ie, HIV incidence). 
We only included articles published in English.
We systematically searched MEDLINE, Embase, Web 
of Science, Global Health, and CINAHL using the search 
terms “HIV incidence”, “adolescents”, and “girls and 
young women”. Medical subject headings were used and 
truncation, synonyms, and alternative spelling were 
added to the search. In addition to the database searches, 
we searched the citations from key papers identified for 
inclusion in the review.
KdG, IB, and CT applied the inclusion criteria to all 
studies identified through the database searches. SS 
independently did the eligibility assessment using the 
inclusion criteria for 20% of the studies at the initial 
screening of titles, abstracts, and full texts. Assessment 
of agreement was undertaken at each of these stages, and 
any disagreement resolved by consensus after referring 
to the protocol. For studies identified through the search, 
which published directly observed HIV incidence 
estimates within the eligible countries and timeframe, 
but not by age and sex, we contacted the authors to 
request disaggregated estimates.
Standardised data were extracted from each study, 
which were study design, country, location (province or 
district), study period, study population, person-years at 
risk, number of HIV seroconversions, statistical methods 
for incidence estimation (where these were reported), 
and HIV incidence estimates reported for participants up 
to the age of 30 years. Incidence rate was converted to the 
number of new HIV infections per 100 person-years, if a 
different unit was presented by authors. We reviewed 
reported HIV incidence rates by sex, age range, setting, 
and time or year. We used checklists from the Critical 
Appraisal Skills Programme11 and the Joanna Briggs 
Institute12 (for cross-sectional studies) to appraise the 
methodology of included studies.
Data analysis
Analysis of estimates from general population studies 
consisted of three components: construction of forest 
plots, calculation of pooled HIV incidence rates, and 
meta-regression analysis. First, we constructed forest 
plots to summarise HIV incidence rates and 95% CIs by 
sex and age, and stratified by region. When CIs were not 
reported, we derived them using exact methods based on 
a Poisson distribution. Second, we used a random-
effects meta-analysis technique13 to calculate pooled 
estimates of sex and age-specific incidence rates, 
stratified by region, from studies based on prospective 
designs (excluding cross-sectional, assay-based studies), 
when the number of HIV events and risk measured in 
person-years by sex and age were available. Meta-analysis 
models were applied by using natural logarithm HIV 
incidence rates and a corresponding SE. Studies 
reporting zero HIV events posed a challenge for natural 
logarithm function.14 For these studies, we added 0∙5 to 
the number of HIV events and person-years of follow-up 
as correction methods.15
In terms of publication bias and small study effects, 
we neither constructed funnel plots (as this method is 
not recommended for small sample sizes of less than 
ten studies16) nor applied Begg’s or Egger’s tests given 
inadequate numbers of estimates for detection.17,18 Since 
HIV incidence is expected to vary from one setting 
to another, we did not report a statistical test for 
heterogeneity. As a sensitivity analysis for southern 
Africa region, where multiple studies were from the 
same surveillance site, we calculated pooled estimates 
both with and without estimates from that site. Lastly, we 
used meta-regression to assess differences in pooled 
incidence rates by age and sex, within regions.
We did all statistical analyses using Stata (version 15.0).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corres ponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
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Results
Figure 1 summarises the flow of information through 
each phase of the systematic review. 2241 records were 
identified through the database searches and 19 through 
citation screening. After duplicates were removed, 
1224 studies remained, of which a further 1026 were 
excluded based on their title or abstract. In total, we 
examined the full text of 198 studies. Of these studies, 
139 were excluded based on inadequate incidence 
reporting or study design. 43 studies met all inclusion 
criteria identified in the original protocol and reported 
age-specific and sex-specific estimates for HIV incidence. 
16 additional studies did not report HIV incidence 
separately for 15–24-year-old females (but were eligible 
otherwise), and age-disaggregated and sex-disaggregated 
data were sought through contact with study authors. 
This follow-up yielded data from eight more studies, 
for a total of 51 studies included in this systematic review. 
The appendix lists the location and other details of 
eligible studies for which disaggregated data were not 
available.
The 51 studies included were done in nine of the 
ten DREAMS countries: Kenya (n=4), Malawi (n=1), 
Mozambique (n=4), South Africa (n=21), Swaziland (n=1), 
Tanzania (n=2), Uganda (n=8), Zambia (n=1), Zimbabwe 
(n=4), and multi country studies (n=5). No eligible studies 
from Lesotho were identified. 27 studies reported 
incidence estimates from general population-based 
samples (table 1)—ie, census-based surveillance or 
random samples from household sampling frames. The 
other 24 studies reported estimates from subpopula-
tions of young people, on the basis of high-risk sexual 
behaviour or venue-based samples drawn from schools, 
bars, guesthouses, clinics, or fishing villages (table 2).
Most estimates were drawn from prospective studies 
(45 [88%] of 51 studies), with cohort data from observa-
tional research or intervention trials, while six (12%) 
studies estimated recent HIV infection among HIV-
positive samples from cross-sectional surveys.7,21,22,33,40,42 
The cohort studies estimated incidence from repeated 
observations, most often imputing the timing of sero-
conversion from the midpoint or a random-point 
between the latest-negative and earliest-positive antibody 
test dates. Details of statistical methods for estimation 
were not always available or consistently reported across 
studies.
Nationally representative estimates were available for 
five countries. In Swaziland, estimates were drawn from a 
national cohort, whereas in the four other countries, recent 
HIV infection among HIV-positive samples was estimated 
from cross-sectional surveys. In 2015–16, Population 
Health Impact Assessments (PHIA) in Malawi, Zambia, 
and Zimbabwe combined HIV-1 limiting antigen enzyme 
immunoassay with a viral load of more than 1000 copies 
per mL and an optical density of 1∙5 or less as a classi-
fication for a recent HIV infection (as per WHO’s 
recommended algorithm).68 Two nationally representative 
surveys in South Africa estimated recent infection with 
differing methodologies: the earliest survey in 2005 used 
BED capture enzyme immunoassay, and confirmatory 
specimens with a cutoff optical density of 0∙8 were con-
sidered to be a recent HIV infection;33 and the 2012 study 
applied the WHO recommended algorithm.7,69
Other population-based studies were in HIV surveil-
lance systems with large (often district-wide), open 
community cohorts, in which members can leave or be 
added over time, in Siaya, Kenya (n=1),19,20 Masaka, 
Uganda (n=2),14,36 Rakai, Uganda (n=3),37–39 uMkhanyakude, 
South Africa (n=11),3,23–32 and Manicaland, Zimbabwe 
(n=1).41 One closed (with fixed membership) general 
population cohort in Mbeya, Tanzania,34 and a district-
wide home-based counselling and testing programme in 
eastern Uganda were also identified.35
8 studies excluded
2260 records identified
1036 duplicates removed
1224 records screened
198 full-text articles 
assessed for eligibility 
43 studies met inclusion criteria
1026 records excluded based on title 
or abstract
139 full-text articles excluded
16 full-text articles followed up for 
disaggregated incidence data 
from study authors
2241 records identified through database 
searching
19 additional records identified though 
citation screening
8 studies included with 
disaggregated data from authors
51 studies included in analyses
27 from general populations
24 from subpopulations
8 general population studies 
excluded from pooled estimates 
1 due to incomplete information
6 had estimates based on 
recency assays (vs cohorts)
1 had most data collected 
before 2004 
19 general population studies 
contributing observations to 
pooled estimates 
Figure 1: Flow of information through the search and screening phases of the review
See Online for appendix
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The studies that sampled from groups considered to be 
at high-risk, or of higher risk than the gen eral populations, 
included female sex workers in Zimbabwe,61 South Africa,53 
and Kenya;44,45 young women reporting multiple sexual 
partners or pregnant women in Mozambique46–48 and 
Zimbabwe;62 women recruited from bars and guesthouses 
in Kenya43 and Tanzania;58 and young men and women 
residing in fishing communities in Uganda.59,60 A number 
of intervention trials (in South Africa and multicountry 
studies) enrolled women either from family planning and 
clinics for sexually transmitted infections (STIs)50,54 or 
outreach events,57 or based on recent sexual behaviour—eg, 
three or more sexual partners in the past 3 months.53,56,63–67 
Finally, three studies were sampled from settings not 
associated with HIV risk, such as youths attending 
school in South Africa’s Eastern Cape52 or Mpumalanga 
Country Location, 
region, 
or setting
Study design 
(measure of HIV 
incidence)
Year HIV incidence per 100 PYs (95% CIs)*
Females Males
Age 15–19 years Age 20–24 years Age 25–30 years Age 15–19 years Age 20–24 years Age 25–30 years
Birdthistle et al 
(2018)19 and 
Borgdorff et al 
(2018)20
Kenya Gem 
subcounty, 
Siaya county
Prospective cohort 
(direct estimates)
2011–16 0∙43 
(2∙96–5∙91); 
n=35; 
PYs=8236
1∙12 
(0∙80–1∙52); 
n=40; PYs=3574
0∙96 
(0∙73–1∙25)†; 
n=56; 
PYs=5800
0∙32 
(0∙19–0∙51);
n=17; 
PYs=5300
Included in 
previous 
estimate
1∙07 
(0∙71–1∙57)†; 
n=27; 
PYs=2500
Blaizot et al 
(2017)21
Kenya Ndhiwaza 
subcounty, 
Siaya county 
(former 
province of 
Nyanza)
Cross-sectional 
survey (test for 
recent infection; 
estimates from 
assay 
measurements)
2012 BioRad avidity 
assay: 2∙07 
(0∙85–3∙29); 
n=18; N=184; 
limiting antigen 
avidity enzyme 
immunoassay 
2∙50 (1∙10–4∙50); 
n=11; N=184
Included in 
previous 
estimate
BioRad avidity 
assay: 1∙90 
(0∙00–3∙90)†; 
n=16; N=359; 
limiting antigen 
avidity enzyme 
immunoassay: 
2∙40 
(0∙20–5∙10)†; 
n=8; N=359
BioRad avidity 
assay: 0∙25 
(0∙00–0∙73); 
n=2; N=25; 
limiting antigen 
avidity enzyme 
immunoassay: 
0∙30 
(0∙00–2∙70); 
n=1; N=25
Included in 
previous 
estimate
BioRad avidity 
assay: 2∙50 
(0∙20–4∙60)†; 
n=9; N=121; 
limiting antigen 
avidity enzyme 
immunoassay: 
0∙96 
(0∙00–2∙79)†; 
n=2; N=121
Malawi Ministry 
of Health 
(2017)22
Malawi National Cross-sectional (test 
for recent infection)
2015–16 0∙40 
(0∙04–0∙77)
Included in 
previous 
estimate
0∙87 
(0∙11–1∙63)†
0∙05 
(0∙00–0∙19)
Included in 
previous 
estimate
0∙40 
(0∙00–0∙91)†
Vandormael 
et al (2014)23
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2004–12 4∙91 
(4∙48–5∙39); 
n=451; 
PYs=9179
7∙80 
(7∙19–8∙46); 
n=583; 
PYs=7478
6∙50 
(5∙66–7∙45)‡; 
n=204; 
PYs=3140
0∙90 
(0∙71–1∙12); 
n=75; 
PYs=8373
3∙28 
(2∙85–3∙78); 
n=192; 
PYs=5848
4∙66 
(3∙82–5∙68)‡; 
n=97; 
PYs=2082
Harling et al 
(2014)24
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal 
(sexually active)
Prospective cohort 
(direct estimates)
2003–12 7∙79 
(6∙59–9∙22)
8∙63 
(7∙63–9∙77); 
n=458; 
PYs=5913
5∙63 
(4∙46–7∙11)‡
∙∙ ∙∙ ∙∙
Rosenberg et al 
(2013)25
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2006–11 4∙37 
(3∙79–5∙04); 
n=190; 
PYs=4344
Included in 
previous 
estimate
∙∙ 1∙38 
(1∙07–1∙79); 
n=58; 
PYs=4193
Included in 
previous 
estimate
∙∙
Tanser et al 
(2011)26
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2004–09 5∙10 
(4∙58–5∙67); 
n=342; 
PYs=6701∙51
7∙47 
(6∙33–8∙76); 
n=152; 
PYs=2033∙72
5∙18 
(3∙88–6∙77)‡; 
n=53; 
PYs=1023∙38
∙∙ ∙∙ ∙∙
Tanser et al 
(2013)27
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2004–11 4∙43 
(3∙96–4∙95); 
n=312; 
PYs=7036
6∙49 
(5∙86–7∙18); 
n=375; 
PYs=5776
5∙51 
(4∙64–6∙54)‡; 
n=131; 
PYs=2376
0∙74 
(0∙56–0∙99); 
n=48; 
PYs=6458
2∙53 
(2∙10–3∙05); 
n=109; 
PYs=4310
4∙43 
(3∙50–5∙61)‡; 
n=69; 
PYs=1557
Dobra et al 
(2017)3
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2004–14 5∙10 
(4∙61–5∙60); 
n=388; 
PYs=7604
9∙11 
(8∙40–9∙82); 
n=570; 
PYs=6257
7∙03 
(6∙07–7∙99)‡; 
n=192; 
PYs=2732
0∙91 
(0∙70–1∙12); 
n=72; 
PYs=7908
3∙69 
(3∙19–4∙19); 
n=203; 
PYs=5504
5∙79 
(4∙79–6∙80)‡; 
n=121; 
PYs=2088
Akullian et al 
(2017)28
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2004–15 5∙6 
(5∙3–5∙9); 
n=1173; 
PYs=21 043
Included in 
previous 
estimate
3∙1 
(2∙9–3∙4)§; 
n=615; 
PYs=19 863
1∙7 
(1∙5–1∙9); 
n=296; 
PYs=17 915
Included in 
previous 
estimate
3∙6 (3∙1–4∙2)†; 
n=184; 
PYs=5061
Chimbindi et al 
(2018)29
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2006–10 4∙71 
(4∙10–5∙41); 
n=254; 
PYs=5395
7∙62 
(6∙71–8∙65); 
n=340; 
PYs=4462
∙∙ ∙∙ ∙∙ ∙∙
(Table 1 continues on next page)
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Country Location, 
region, or 
setting
Study design 
(measure of HIV 
incidence)
Year HIV incidence per 100 PYs (95% CIs)*
Females Males
Age 15–19 years Age 20–24 years Age 25–30 years Age 15–19 years Age 20–24 years Age 25–30 years
(Continued from previous page)
Chimbindi et al 
(2018)29
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2011–15 4∙54 
(3∙89–5∙30); 
n=197; 
PYs=4330
7∙45 
(6∙51–8∙51); 
n=289; 
PYs=3881
∙∙ ∙∙ ∙∙ ∙∙
Baisley et al 
(2018)30
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2006–10 ∙∙ ∙∙ ∙∙ ∙∙ 3∙08 
(2∙49–3∙82); 
n=120; 
PYs=3897
4∙43 
(3∙34–5∙87)‡; 
n=68; 
PYs=1530
Baisley et al 
(2018)30
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2011–15 ∙∙ ∙∙ ∙∙ ∙∙ 2∙58 
(2∙00–3∙32); 
n=81; PYs=3121
4∙04 
(3∙07–5∙31)‡; 
n=73; PYs=1793
Bärnighausen 
et al (2008)31¶
South 
Africa
uMkhanyakude 
district, 
KwaZulu-Natal
Prospective cohort 
(direct estimates)
2003–07 3∙9 
(2∙9–5∙3)
5∙6 
(4∙0–8∙0)
8∙0 
(4∙9–13∙0)‡
1∙0 
(0∙5–1∙8)
2∙8 
(1∙6–4∙8)
8∙7 
(4∙8–15∙8)‡
Unpublished 
data from Iwuji 
et al (2018)32
South 
Africa
uMkhanyakude 
district (Hlabisa 
subdistrict), 
KwaZulu-Natal
Intervention (direct 
estimates; control 
arm)
2012–15 5∙54 
(4∙64–6∙45)||; 
n=144; 
PYs=2597
6∙93 
(5∙75–8∙11); 
n=133; PYs=1919
6∙34 
(4∙77–7∙90)‡; 
n=63; PYs=994
0∙61 
(0∙28–0∙94)||; 
n=13; PYs=2144
2∙02 
(1∙19–2∙84); 
n=23; PYs=1141
1∙06 
(0∙21–1∙90)‡; 
n=6; PYs=567
Shisana et al 
(2005)33
South 
Africa
National Cross-sectional (test 
for recent infection; 
estimates from assay 
measurements)
2005 6∙5 (2∙3–10∙7); 
n=61; N=2335
Included in 
previous 
estimate
7∙1 (2∙6–11∙6)†;
n=48; N=2013 
(for men and 
women 
combined)
0∙8 (0∙0–3∙4); 
n=9; N=1785
Included in 
previous 
estimate
7∙1 (2∙6–11∙6)†; 
n=48; N=2013 
(for men and 
women 
combined)
Shisana et al 
(2014)7
South 
Africa
National Cross-sectional (test 
for recent infection; 
estimates from assay 
measurements)
2012 2∙54 
(2∙04–3∙04); 
N=3092
Included in 
previous 
estimate
1∙62 
(1∙30–1∙94)**; 
N=8857
0∙55 
(0∙45–0∙65); 
N=2798
Included in 
previous 
estimate
1∙29 
(0∙91–1∙67)**; 
N=5959
Justman et al 
(2017)6††
Swaziland National Prospective cohort 
(direct estimates)
2010–11 3∙8 (2∙6–5∙6)‡‡; 
n=16∙0; 
PYs=421∙1
4∙3 (3∙3–5∙6); 
n=36∙4; 
PYs=846∙5
2∙0 (1∙2–3∙2)‡; 
n=10∙2; 
PYs=510
0∙8 (0∙4–1∙9)‡‡; 
n=4∙0; 
PYs=500
1∙6 (1∙1–2∙5); 
n=16∙0; 
PYs=1000
2∙6 (1∙7–4∙0)‡; 
n=16∙9; 
PYs=650
Unpublished 
data from Geis 
et al (2011)34§§
Tanzania Mbeya Prospective cohort 
(direct estimates)
2005–06 0¶¶ 2∙60 
(1∙51–4∙47)
0∙26 
(0∙04–1∙84)‡
0¶¶ 1∙36 
(0∙57–3∙27)
0∙72 
(0∙18–2∙88)‡
Okiria et al 
(2014)35††||||
Uganda Kumi district 
(rural)
Prospective cohort 
(direct estimates)
2006–08 0∙38 
(0∙19–0∙66)***; 
n=11; 
PYs=2894∙7
∙∙ 0∙68 
(0∙44–1∙01)‡; 
n=25; 
PYs=3676∙5
0∙26 
(0∙07–0∙66)***; 
n=4; 
PYs=1538∙5
∙∙ 0∙28 
(0∙09–0∙65)‡; 
n=5; 
PYs=1785∙7
Biraro et al 
(2013)36††
Uganda Masaka Prospective cohort 
(direct estimates)
1990–
2007
0∙57 
(0∙44–0∙74)***; 
n=58; 
PYs=10 104
1∙19 
(0∙91–1∙53); 
n=59; PYs=4962
0∙95 
(0∙68–1∙30)‡; 
n=39; PYs=4108
0∙09 
(0∙04–0∙16)***; 
n=10; 
PYs=11 261
0∙79 
(0∙55–1∙09); 
n=36; PYs=4554
1∙35 
(0∙99–1∙80)‡; 
n=46; PYs=3415
Unpublished 
data from 
Grabowski et al 
(2017)37
Uganda Rakai Prospective cohort 
(direct estimates)
2005–11 1∙03 
(0∙64–1∙57); 
n=19; PYs=1840
1∙47 
(1∙12–1∙90); 
n=55; PYs=3730
1∙47 
(1∙15–1∙84)‡; 
n=70; PYs=4772
0∙30 
(0∙12–0∙60); 
n=6; PYs=2023
0∙90 
(0∙61–1∙28); 
n=28; PYs=3107
1∙73 
(1∙31–2∙23)‡; 
n=55; PYs=3173
Unpublished 
data from 
Grabowski et al 
(2017)37
Uganda Rakai Prospective cohort 
(direct estimates)
2011–16 0∙59 
(0∙31–1∙01); 
n=11; PYs=1857
1∙53 
(1∙13–2∙01); 
n=47; PYs=3077
1∙12 
(0∙81–1∙50)‡; 
n=41; PYs=3664
0∙16 
(0∙05–0∙38); 
n=4; PYs=2466
0∙40 
(0∙21–0∙68); 
n=12; PYs=2973
1∙26 
(0∙89–1∙72)‡; 
n=55; PYs=2783
Santelli et al 
(2013)38
Uganda Rakai (sexually 
experienced)
Prospective cohort 
(direct estimates)
1998–
2008
1∙49 
(1∙06–2∙04); 
n=39; PYs=2614
1∙38 
(1∙13–1∙66); 
n=109; 
PYs=7907
∙∙ 0∙36 
(0∙14–0∙73); 
n=7; PYs=1969
1∙02 
(0∙76–1∙35); 
n=49; 
PYs=4803
∙∙
Santelli et al 
(2015)39††
Uganda Rakai (sexually 
experienced)
Prospective cohort 
(direct estimates)
2006–09 0∙63 
(0∙20–1∙47); 
n=5; PYs=793∙7
1∙31 
(0∙82–1∙98); 
n=22; 
PYs=1679∙4
∙∙ 0∙22 
(0∙03–0∙79); 
n=2; PYs=909∙1
0∙79 
(0∙38–1∙45); 
n=10; 
PYs=1265∙8
∙∙
(Table 1 continues on next page)
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province55 and a youth clinic in Maputo, Mozambique,49 
and non-pregnant women in KwaZulu-Natal, South 
Africa.51
HIV incidence estimates from the general population 
studies are summarised along with study characteristics 
in table 1 and by age, sex, and region in figures 2 and 3. 
National estimates of incidence were highest in South 
Africa (6∙5 cases per 100 person-years among females 
aged 15–24 years in 2005,33 and 2∙54 cases in 20127) and 
Swaziland, where the national rates observed in 
2010–11 were 3∙8 cases per 100 person-years among 
women aged 18–19 years and 4∙3 cases among those 
aged 20–24 years.6 More recently, national surveys 
done in 2015–16 estimated HIV incidence in Malawi to 
be at 0∙4%, in Zambia at 1∙07%, and in Zimbabwe at 
0∙53% among females aged 15–24 years.22,40,42
Among general populations of adolescent girls and 
young women in subnational areas, rates varied sub-
stantially across settings (table 1). Estimates were highest 
among sexually active young women in one of the 
earlier studies from KwaZulu-Natal (7∙79 infections per 
100 person-years for those aged 15–19 years; 8∙63 among 
females aged 20–24 years between 2003 and 2012),24 and 
lowest in Uganda (eg, 0∙38 cases per 100 person-years 
among females aged 13–19 years in the Kumi district, 
2006–08).35 Two studies with small sample sizes observed 
zero seroconversions—eg, among those younger than 
20 years in Mbeya (Tanzania) and Masaka (Uganda).14,34
Among studies with high-risk populations of women, 
HIV incidence rates reached 12∙4 by 2015 among females 
aged 15–19 years in Ugandan fishing communities 
(table 2).59,60 Young female sex workers (younger than 
Country Location, 
region, or 
setting
Study design 
(measure of HIV 
incidence)
Year HIV incidence per 100 PYs (95% CIs)*
Females Males
Age 15–19 years Age 20–24 years Age 25–30 years Age 15–19 years Age 20–24 years Age 25–30 years
(Continued from previous page)
Santelli et al 
(2015)39††
Uganda Rakai (sexually 
experienced)
Prospective cohort 
(direct estimates)
2008–11 0∙23 
(0∙03–0∙83); 
n=2; 
PYs=869∙6
1∙55 
(0∙95–2∙39); 
n=20; 
PYs=1290∙3
∙∙ 0∙19 
(0∙02–0∙69); 
n=2; 
PYs=1052∙6
1∙23 
(0∙69–2∙03); 
n=15; 
PYs=1219∙5
∙∙
Unpublished 
data from 
Ruzagira et al 
(2011)14
Uganda Masaka Prospective cohort 
(direct estimates)
2004–07 0; 
n=0; PYs=64∙1
0; 
n=0; PYs=206∙8
2∙0 
(0∙8–4∙8)‡; n=5; 
PYs=252∙1
0; 
n=0; 
PYs=26
2∙5 
(0∙8–7∙7); n=3; 
PYs=121∙4
2∙2 
(0∙7–6∙8)‡; n=3; 
PYs=139∙5
Zambia Ministry 
of Health 
(2017)40
Zambia National Cross-sectional (test 
for recent infection; 
estimates from assay 
measurements)
2015–16 1∙07 
(0∙52–1∙62)
Included in 
previous 
estimate
1∙16 
(0∙46–1∙86)†
0∙08 
(0∙00–0∙25)
Included in 
previous 
estimate
0∙25 
(0∙00–0∙63)†
Unpublished 
data from 
Schaefer et al 
(2017)41
Zimbabwe Manicaland Prospective cohort 
(direct estimates)
2003–13 0∙99 
(0∙71–1∙38); 
n=35; 
PYs=3530∙20
1∙62 
(1∙26–2∙08); 
n=62; 
PYs=3830∙1
1∙45 
(1∙12–1∙88)‡; 
n=57; 
PYs=3930∙9
0∙26 
(0∙15–0∙46); 
n=12; 
PYs=4557∙3
0∙83 
(0∙55–1∙26); 
n=22; 
PYs=2642∙3
1∙47 
(1∙04–2∙06)‡; 
n=22; 
PYs=2250∙2
Unpublished 
data from 
Schaefer et al 
(2017)41
Zimbabwe Manicaland Prospective cohort 
(direct estimates)
2004–08 1∙94 
(1∙50–2∙51); 
n=59; 
PYs=3039∙8
Included in 
previous 
estimate
∙∙ 0∙93 
(0∙64–1∙36); 
n=27; 
PYs=3895∙0
Included in 
previous 
estimate
∙∙
Unpublished 
data from 
Schaefer et al 
(2017)41
Zimbabwe Manicaland Prospective cohort 
(direct estimates)
2006–11 0∙72 
(0∙46–1∙14); 
n=19; 
PYs=2625∙4
Included in 
previous 
estimate
∙∙ 0∙15 
(0∙06–0∙39); 
n=4; 
PYs=2740∙5
Included in 
previous 
estimate
∙∙
Unpublished 
data from 
Schaefer et al 
(2017)41
Zimbabwe Manicaland Prospective cohort 
(direct estimates)
2009–13 1∙12 
(0∙72–1∙76); 
n=19; 
PYs=1695∙0
Included in 
previous 
estimate
∙∙ 0∙19 
(0∙06–0∙60); 
n=3; 
PYs=1564∙2
Included in 
previous 
estimate
∙∙
Zimbabwe 
MOHCC 
(2017)42
Zimbabwe National Cross-sectional (test 
for recent infection; 
estimates from assay 
measurements)
2015–16 0∙53 
(0∙13–0∙93)
Included in 
previous 
estimate
1∙11 
(0∙41–1∙80)†
0∙14 
(0∙00–0∙37)
Included in 
previous 
estimate
0∙48 
(0∙00–1∙05)†
PYs=person-years. Included in previous estimate=data for age groups 15–19 years and 20–24 years are combined into one estimate (as given in adjacent cell). MOHCC=Ministry of Health and Child Care. 
*Cases (n) and PYs are shown when available. Total sample size (N) is given when PYs were not available. †Up to age 34 years. ‡Up to age 29 years. §Up to age 49 years. ¶n=170; PYs=5253 for all men and women 
aged 15–34 years. ||Between ages 16 years and 19 years. **Older than 25 years. ††PYs or 95% CIs, or both, were calculated from data in study; CIs were calculated using exact Poisson CIs. ‡‡Between ages 18 years 
and 19 years. §§n=101; PYs=7471 for study incorporating data from 2003 to 2004 (not included here) and 2005 to 2006 (included here). ¶¶Between ages 17 years and 19 years. ||||Data from a home-based HIV 
counselling and testing programme offered community wide. ***Between ages 13 years and 19 years.
Table 1: HIV incidence estimates among young women and men in samples representing the general population
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25 years) experienced rates of 13∙20 (95% CI 6∙59–23∙62) 
cases per 100 person-years in Durban, South Africa,53 and 
10∙8 (8∙1–16∙1) in Zimbabwe.61 High rates of 10∙26 were 
observed among girls aged 16–19 years recruited from 
bars and guesthouses in Tanzania in 2003–05.58 Rates 
among females aged 14–19 years attending urban family 
planning and STI clinics in KwaZulu-Natal (2004–07) were 
lower, at 4∙2 cases per 100 person-years,50 and a cohort of 
female sex workers aged 15–24 years in Kenya observed 
an incidence of less than 1%.44,45 Sample sizes were small 
and 95% CIs were wide for many of these studies.
Three of four studies done in Mozambique reported 
high HIV incidence rates among subpopulations of 
young women, including pregnant women (4∙9 among 
those aged 18–19 years in 2008–11),46 women with 
multiple sexual partners aged 18–24 years in Beira 
(7∙1 per 100 person-years in 2009–12),47 and women aged 
18–24 years in bars and guesthouses in Chokwe (4∙8 in 
2010–12).48 By contrast, incidence was lower, at 1∙49, 
among women aged 18–24 years recruited from a youth 
clinic in Maputa, 2009–11.49
Among young males, incidence was less than 
1% among those aged 15–19 years in all general 
population studies. The highest rates were reported 
among males in fishing communities—eg, previously 
unpublished data from fishing villages in Masaka from 
2012 to 2015 showed an exceptionally high HIV incidence 
in adolescent boys (19∙2 cases per 100 person-years; 
95% CI 6∙2–59∙6).59
In studies with general populations of both males and 
females, HIV incidence rates among adolescent females 
exceeded their male peers in all settings and countries 
included. In South Africa and Swaziland, the rate among 
females aged 15–19 years was four-to-five times greater 
than among males. This difference narrows in the age 
range of those older than 25 years, when incidence 
among men escalates. For example, in uMkhanyakude, 
the large difference in incidence for males and females 
aged 15–19 years (5∙10 per 100 person-years among 
females and 0∙91 per 100 person-years among males)3 
reduces as male incidence accelerates from age 20 years 
(7∙03 per 100 person-years among females and 5∙79 per 
100 person-years among males).
In the general population studies, female HIV incidence 
rates rose between the ages 15–19 years, and typically 
peaked among those aged 20–24 years before declining or 
stabilising from age 25 years. In uMkhanyakude, for 
example, multiple studies show that incidence rates were 
highest among females aged 20–24 years and decline 
thereafter.3,23,24,26,27 In the same communities, rates accel-
erated later among young men; typically remaining low 
(<1%) among teenagers before increasing through their 
twenties.
By contrast, among high-risk populations, HIV inci-
dence rates were commonly highest among the youngest 
females, peaking during adolescence (table 2). For 
example, in the Mozambique studies with high-risk 
populations, the highest rates were reported among 
the youngest age groups—eg, 4∙92 among pregnant 
women aged 18–19 years versus 3∙39 among those aged 
20–24 years and 3·49 among those aged 25–29 years.46 
Similarly, in northwestern Tanzania, females aged 
16–19 years from bars and guesthouses experienced more 
than double the risk of those aged 20–29 years.58 Incidence 
rates were also exceptionally high among the youngest 
females (aged 15-19 years) in fishing communities in 
Female subgroup
Schaefer et al (2017)41
Justman et al (2017)6
Bärnighausen et al (2008)31
Tanser et al (2013)27
Chimbindi et al (2018)29
Chimbindi et al (2018)29
Vandormael et al (2014)23
Tanser et al (2011)26
Dobra et al (2017)3
Iwuji et al (2018)32
Harling et al (2014)24
Male subgroup
Schaefer et al (2017)41
Iwuji et al (2018)32
Tanser et al (2013)27
Justman et al (2017)6
Vandormael et al (2014)23
Dobra et al (2017)3
Bärnighausen et al (2008)31
2003–13
2010–11
2003–07
2004–11
2011–15
2006–10
2004–12
2004–09
2004–11
2012–15
2003–12
2003–13
2012–15
2004–11
2010–11
2004–12
2004–11
2003–07
0·99 (0·71–1·38)
3·80 (2·60–5·60)
3·90 (2·90–5·30)
4·43 (3·96–4·95)
4·54 (3·89–5·30)
4·71 (4·10–5·41)
4·91 (4·48–5·39)
5·10 (4·58–5·67)
5·10 (4·61–5·60)
5·54 (4·64–6·45)
7·79 (6·59–9·22)
0·26 (0·15–0·46)
0·61 (0·28–0·94)
0·74 (0·56–0·99)
0·80 (0·40–1·90)
0·90 (0·71–1·12)
0·91 (0·70–1·12)
1·00 (0·50–1·80)
Incidence rate (95% CI)Year
A
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Uganda.59,60 However, in women sampled from family 
planning and STI clinics in KwaZulu-Natal, rates were 
higher for women aged 20–29 years than for those aged 
14–19 years.50
Few studies reported trends in HIV incidence over 
time, and the findings vary. Between 1999 and 2011, trends 
in HIV incidence by sex and age were reported in Rakai, 
Uganda. Among adolescent girls aged 15–19 years, 
incidence fluctuated between 1999 and 2004 (between 
0∙37% and 1∙94%), and subsequently declined with each 
round through 2011 (p=0∙006).39 More recently, between 
2005–11 and 2011–16, rates declined from 1∙03 to 
0∙59 among females aged 15–19 years and from 0∙30 to 
0∙16 among males of the same age.37 Meanwhile, rates 
from Ugandan fishing communities in 2012–15 match or 
exceed estimates from Ugandan fishing communities in 
2009–11,59,60 suggesting that risk in fishing communities 
has not declined with time.
Estimates from the ongoing surveillance site in 
Manicaland, Zimbabwe, suggest declines among both 
young females and males between 2003 and 2013, with 
a substantial decrease between 2004–08 and 2006–11, 
before a slight increase again in more recent years 
of 2009–13.41
In the two national incidence surveys in South Africa 
(with representative cross-sectional samples), in 2005 
and 2012, incidence reported among females aged 
15–24 years declined from 6∙5 (95% CI 2∙3–10∙7) to 
2∙54 (2∙04–3∙04); and among males of the same age 
from 0∙8 (0∙0–3∙4) to 0∙55 (0∙45–0∙65). However, the 
different methods used for estimating HIV incidence 
in the two surveys might preclude their comparability.7,33 
Female subgroup
Malawi Ministry of Health (2017)22 
Zimbabwe MOHCC (2017)42 
Schaefer et al (2017)41 
Zambia Ministry of Health (2017)40 
Schaefer et al (2017)41 
Schaefer et al (2017)41 
Schaefer et al (2017)41 
Shisana et al (2014)7 
Justman et al (2017)6 
Rosenberg et al (2013)25 
Bärnighausen et al (2008)31 
Akullian et al (2017)28 
Tanser et al (2013)27 
Shisana et al (2005)33 
Iwuji et al (2018)32 
Chimbindi et al (2018)29 
Tanser et al (2011)26
Chimbindi et al (2018)99 
Vandormael et al (2014)23 
Harling et al (2014)24 
Dobra et al (2017)3
Male subgroup
Malawi Ministry of Health (2017)22 
Zambia Ministry of Health (2017)40 
Zimbabwe MOHCC (2017)42 
Schaefer et al (2017)41 
Schaefer et al (2017)41 
Shisana et al (2014)7 
Shisana et al (2005)33 
Schaefer et al (2017)41 
Schaefer et al (2017)41 
Rosenberg et al (2013)25 
Justman et al (2017)6 
Akullian et al (2017)28
Iwuji et al (2018)32 
Tanser et al (2018)27 
Baisley et al (2018)30 
Bärnighausen et al (2008)31 
Baisley et al (2018)30 
Vandormael et al (2014)23 
Dobra et al (2017)3 
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2015–16
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2015–16
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2003–13
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2006–11
2003–07
2004–15
2004–11
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2004–09
2006–10
2004–12
2003–12
2004–11
2015–16
2015–16
2015–16
2006–11
2009–13
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2005–05
2003–13
2004–08
2006–11
2010–11
2004–15
2012–15
2004–11
2011–15
2003–07
2006–10
2004–12
2004–11
Incidence rate (95% CI)
0·40 (0·04–0·77)
0·53 (0·13–0·93)
0·72 (0·46–1·14)
1·07 (0·52–1·62)
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1·62 (1·26–2·08)
1·94 (1·50–2·51)
2·54 (2·04–3·04)
4·30 (3·30–5·60)
4·37 (3·79–5·04)
5·60 (4·00–8·00)
5·60 (5·30–5·90)
6·49 (5·86–7·18)
6·50 (2·30–10·70)
6·93 (5·75–8·11)
7·45 (6·51–8·51)
7·47 (6·33–8·76)
7·62 (6·71–8·65)
7·80 (7·19–8·46)
8·63 (7·63–9·77)
9·11 (8·40–9·82)
0·05 (0·00–0·19)
0·08 (0·00–0·25)
0·14 (0·00–0·37)
0·15 (0·06–0·39)
0·19 (0·06–0·60)
0·55 (0·45–0·65)
0·80 (0·00–3·40)
0·83 (0·55–1·26)
0·93 (0·64–1·36)
1·38 (1·07–1·79)
1·60 (1·10–2·50)
1·70 (1·50–1·90)
2·02 (1·19–2·84)
2·53 (2·10–3·05)
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Meanwhile, there is no evidence of a decline in 
South Africa’s highest-incidence settings by 2015. 
Estimates from the population-based HIV surveillance 
system with an open-community cohort in the 
uMkhanyakude district, KwaZulu-Natal, show no decline 
in rates between 2006–10 and 2011–15 among adolescent 
girls or young women29 or among young men aged 
20–29 years.30 Newly obtained age-disaggregations of 
HIV incidence among female sex workers in Mombasa, 
Kenya, show that risk among those aged 15–19 years 
(2∙9%) matched that of older women aged 25–29 years 
(3∙0%) between 1998 and 2004. More recently, from 
2005 to 2012, incidence observed in the same cohort 
study decreased (eg, zero among females aged 
15–19 years and <1% among all older age groups), 
indicating reduction of risk over time among sex workers 
of all ages.44,45
Of the 27 general population cohort studies, infor mation 
about HIV events (directly estimated) needed for pooled 
sex and age calculations was available in 19 (70%) studies 
(table 3). The pooled rates are highest among young 
women in studies from the Southern African Development 
Community (SADC) region, and exceed 4% per year in all 
age groups from 15–29 years (this incidence decreases to 
<2% when studies from uMkhanyakude, South Africa, are 
excluded). Among young men, the pooled rates are also 
higher in SADC than the East African Community (EAC) 
region, and highest among those aged 25–29 years in both 
SADC (3∙34 per 100 person-years, 95% CI 2∙58–4∙34) and 
EAC (1∙32 per 100 person-years, 0∙93–1∙86).
Overall, the sex differential in HIV risk is greatest 
among those aged 15–19 years. Meta-regression results 
offer statistical evidence for a difference in the pooled 
incidence rate among young women aged 15–19 years in 
SADC (pooled relative risk 5∙94, 95% CI 3∙39–10∙44), 
and those aged 20–24 years (2∙65, 1∙39–5∙06), compared 
with their male counterparts in SADC, and no meaning-
ful difference was found between males and females 
aged 25–29 years. For the EAC, meta-regression results 
indicated higher risk among young women aged 
15–19 years (pooled relative risk 3∙22, 95% CI 1∙51–6∙87) 
compared with EAC men of the same age, whereas no sex 
difference was found in the age groups of 20–24 years and 
25–29 years.
Discussion
Accurate estimates of HIV incidence among targeted 
groups can be an essential tool in monitoring transmission 
Female subgroup
YearC Incidence rate (95% CI)
Malawi Ministry of Health (2017)22 
Zimbabwe MOHCC (2017)42 
Zambia Ministry of Health (2017)40 
Schaefer et al (2017)41
Shisana et al (2014)7
Justman et al (2017)6
Akullian et al (2017)28
Tanser et al (2011)26
Tanser et al (2013)27
Harling et al (2014)24
Iwuji et al (2018)32
Vandormael et al (2014)23
Dobra et al (2017)3
Bärnighausen et al (2008)31
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Zambia Ministry of Health (2017)40 
Malawi Ministry of Health (2017)221 
Zimbabwe MOHCC (2017)42 
Iwuji et al (2018)32
Shisana et al (2014)7
Schaefer et al (2017)41
Justman et al (2017)6
Akullian et al (2017)28
Baisley et al (2018)30
Tanser et al (2013)27
Baisley et al (2018)30
Vandormael et al (2014)23
Dobra et al (2017)3
Bärnighausen et al (2008)31
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2015–16
2015–16
2003–13
2012–12
2010–11
2004–15
2004–09
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2003–12
2012–15
2004–12
2004–11
2003–07
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2015–16
2015–16
2012–15
2012–12
2003–13
2010–11
2004–15
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2004–11
2006–10
2004–12
2004–11
2003–07
0·87 (0·11–1·63)
1·11 (0·41–1·80)
1·16 (0·46–1·86)
1·45 (1·12–1·88)
1·62 (1·30–1·94)
2·00 (1·20–3·20)
3·10 (2·90–3·40)
5·18 (3·88–6·77)
5·51 (4·64–6·54)
5·63 (4·46–7·11)
6·34 (4·77–7·90)
6·50 (5·66–7·45)
7·03 (6·07–7·99)
8·00 (4·90–13·00)
0·25 (0·00–0·63)
0·40 (0·00–0·91)
0·48 (0·00–1·05)
1·06 (0·21–1·90)
1·29 (0·91–1·67)
1·47 (1·04–2·06)
2·60 (1·70–4·00)
3·60 (3·10–4·20)
4·04 (3·07–5·31)
4·43 (3·50–5·61)
4·43 (3·34–5·87)
4·66 (3·82–5·68)
5·79 (4·79–6·80)
8·70 (4·80–15·80)
0 1 2 5 16
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Figure 2: Forest plots of HIV incidence estimates for young women and men in SADC member countries
Data are incidence rates (cases per 100 person-years) and error bars are 95% CIs. (A) Estimates for those aged 15–19 years. (B) Estimates for those aged 20–24 years. 
(C) Estimates for those aged 25–29 years. SADC=Southern African Development Community. MOHCC=Ministry of Health and Child Care.
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patterns, determining prevention priorities (in terms of 
who and where to target efforts), planning interventions, 
and evaluating progress of programmes. We did a sys-
tematic review and meta-analysis to compile recent, 
direct estimates of HIV incidence among adolescent girls 
(15–19 years) and young women (20–24 years)—who are 
increasingly considered to be key populations in HIV 
prevention strategies—before large investments in tar-
geted prevention began in 2016. Our review has found 
that estimates based on direct observation of incidence are 
Female subgroup
YearA Incidence rate (95% CI)
Ruzagira et al (2011)14
Santelli et al (2015)39
Borgdorff et al (2018)20, Birdthistle et al (2018)19
Biraro et al (2013)36
Grabowski et al (2017)37
Santelli et al (2015)39
Grabowski et al (2017)37
Santelli et al (2013)38
Male subgroup
Ruzagira et al (2011)14
Biraro et al (2013)36
Grabowski et al (2017)37
Santelli et al (2015)39
Santelli et al (2015)39
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Santelli et al (2013)38
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0·30 (0·12–0·60)
0·36 (0·14–0·73)
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Female subgroup
Ruzagira et al (2011)14
Okiria et al (2014)35
Borgdorff et al (2018)20, Birdthistle et al (2018)19
Biraro et al (2013)36
Santelli et al (2015)39
Santelli et al (2013)38
Grabowski et al (2017)37
Grabowski et al (2017)37
Santelli et al (2015)38
Blaizot et al (2017)21
Blaizot et al (2017)21
Geis et al (2011)34
Male subgroup
Blaizot et al (2017)21
Okiria et al (2014)35
Blaizot et al (2017)21
Borgdorff et al (2018)20, Birdthistle et al (2018)19
Grabowski et al (2017)37
Biraro et al (2013)36
Santelli et al (2015)39
Grabowski et al (2017)37
Santelli et al (2013)38
Santelli et al (2015)39
Geis et al (2011)34
Ruzagira et al (2011)14
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2008–11
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2005–06
2012
2006–08
2012
2011–16
2011–16
1990–2007
2006–09
2005–11
1998–2008
2008–11
2005–06
2004–07
0·00 (0·00–1·78)
0·38 (0·19–0·66)
1·12 (0·80–1·52)
1·19 (0·91–1·53)
1·31 (0·82–1·98)
1·38 (1·13–1·66)
1·47 (1·12–1·90)
1·53 (1·13–2·01)
1·55 (0·95–2·39)
2·07 (0·85–3·29)
2·50 (1·10–4·50)
2·60 (1·51–4·47)
0·25 (0·00–0·73)
0·26 (0·07–0·66)
0·30 (0·00–2·70)
0·32 (0·19–0·51)
0·40 (0·21–0·68)
0·79 (0·55–1·09)
0·79 (0·38–1·45)
0·90 (0·61–1·28
1·02 (0·76–1·35)
1·23 (0·69–2·03)
1·36 (0·57–3·27)
2·50
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largely limited to a small number of surveillance sites or 
relatively small observational and intervention studies 
with high-risk groups.
From this constrained and heterogeneous body of 
evidence, some consistent and striking patterns emerge 
about the risk for young people. First, HIV incidence 
rates among adolescent females exceed their male peers 
in all studies and settings. Among the general population 
in high-burden settings, adolescence is a time in which 
HIV risk increased rapidly for females, as high as 
8% incidence among teenage girls in KwaZulu-Natal, 
while remaining less than 1% among male peers in 
almost every study setting.
In the general population studies, female risk continued 
to increase into their mid-twenties, when it typically 
peaked in southern African countries. By contrast, in 
studies of high-risk young women, incidence peaked 
earlier. Among women sampled from sex workers, bar 
workers, guest houses, or STI clinics, risk was often 
higher among teenage girls than older age groups of 
women. This finding may reflect the vulnerability and 
the barriers adolescent girls face in accessing testing and 
treatment services, or negotiating condom use when sex 
is commercial, transactional, with an older partner, or 
within marriage. It might also reflect the risk profiles of 
male partners of high-risk adolescent girls. Alternatively, 
the lower incidence in older women might be due to 
saturation in older age groups in high-risk populations 
(ie, with fewer new people entering these high-risk 
groups at older ages).
Few studies report trends in HIV incidence since 
2005, and the findings are mixed. With previously 
unpublished age and sex disaggregations of data from 
ongoing community surveys in Rakai37 (Uganda) and 
Manicaland41 (Zimbabwe), and among cohorts of sex 
workers in Mombasa45 (Kenya), there are indications that 
incidence among adolescent girls and young women is 
declining. This finding might be due to the indirect 
effects of ART coverage in the community, as well as 
adoption of safer sexual behaviours including condom 
use, or epidemic stage or demographic change.70,71 
However, rates among adolescent girls and young women 
remain high (above elimination targets), and persistently 
higher than male peers. Also, in the highest incidence 
settings of South Africa, as in KwaZulu-Natal and fishing 
communities in Uganda, there was no evidence of a 
decline by 2015. This result suggests that—among other 
factors—availability of ART had not benefited the highest 
risk young women; for example, their sexual partners 
might not be aware of their HIV status or linking into 
care and treatment to achieve viral suppression, as recent 
results of the TasP trial indicate.72 Indeed, ART coverage 
has been lower among HIV-positive men in their twenties 
and thirties (commonly the age group for male sexual 
partners of adolescent girls and young women), relative 
to women and older adults, and this gender discrepancy 
YearC Incidence rate (95% CI)
Incidence rate
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Female subgroup
Geis et al (2011)34
Okiria et al (2014)23
Biraro et al (2013)36
Borgdorff et al (2018)20, Birdthistle et al (2018)19
Grabowski et al (2017)37
Grabowski et al (2017)37
Blaizot et al (2017)21
Ruzagira et al (2011)14
Blaizot et al (2017)21
Male subgroup
Okiria et al (2014)23
Geis et al (2011)34
Blaizot et al (2017)21
Borgdorff et al (2018)20, Birdthistle et al (2018)19
Grabowski et al (2017)37
Biraro et al (2013)36
Grabowski et al (2017)37
Ruzagira et al (2011)14
Blaizot et al (2017)21
2005–06
2006–08
1990–2007
2011–16
2011–16
2005–11
2012
2004–07
2012
2006–208
2005–06
2012
2011–16
2011–16
1990–2007
2005–11
2004–07
2012
0·26 (0·04–1·84)
0·68 (0·44–1·01)
0·95 (0·68–1·30)
0·96 (0·73–1·25)
1·12 (0·81–1·50)
1·47 (1·15–1·84)
1·90 (0·00–3·90)
2·00 (0·80–4·80)
2·40 (0·20–5·10)
0·28 (0·09–0·65)
0·72 (0·18–2·88)
0·96 (0·00–2·79)
1·07 (0·71–1·57)
1·26 (0·89–1·72)
1·35 (0·99–1·80)
1·73 (1·31–2·23)
2·20 (0·70–6·80)
2·50 (0·20–4·60)
Figure 3: Forest plots of HIV incidence estimates for young women and men in EAC member countries
Data are incidence rates (cases per 100 person-years) and error bars are 95% CIs. (A) Estimates for those aged 15–19 years. (B) Estimates for those aged 20–24 years. 
(C) Estimates for those aged 25–29 years. EAC=East African Community.
Articles
e1536 www.thelancet.com/lancetgh   Vol 7   November 2019
has been most pronounced in sub-Saharan Africa.28 
Furthermore, high HIV incidence rates observed among 
young adult men might reflect recent infection and high 
infectiousness among male sexual partners of adolescent 
girls and young women, before they become aware of 
their status and link into care.
The national estimates from South Africa in 2005 and 
2012 suggest a decline in HIV incidence; however, the use 
of different assay methodologies precludes their 
comparability. The earlier survey used the BED assay, 
which is susceptible to overestimation of incidence rates 
(upward bias) in Africa, without the application of context-
specific correction factors.73 More recent national surveys 
across multiple countries have used limiting antigen 
avidity enzyme immunoassays using WHO-recom-
mended algorithms for recent infection,68 and might 
be used to track trends in incidence over time. For 
example, recent Swaziland PHIA results, as shared in a 
2017 conference,74 were compared with estimates from 
the SHIMS 2010–11 cohort study5 to conclude that HIV 
incidence has declined in Swaziland. However, the 
comparability between estimates derived from repeat 
testing within cohorts and from assays is unknown, and 
studies using both methods are needed for validation. 
There are also questions about the interpretation of 
estimates from assays, given the policy shift towards 
immediate treatment meaning that even recently infected 
individuals will increasingly be on treatment, as well as 
the need for viral load data, and the questionable 
performance of assays (eg, wide ranges in false recency 
rates and mean duration of recent infection, and high 
misclassification rates) in different epidemiological con-
texts and HIV subtypes.73,75 Furthermore, the very large 
samples required for estimation—and the relatively small 
number of recent infections identified in the PHIAs—can 
limit meaningful disaggregation of esti mates by age, 
sex, and subnational area, to effectively identify the 
priority places and populations for prevention.
The studies we identified are highly variable in terms of 
study design, size, population, and timing. Where 
possible from available data, we pooled estimates for 
general population studies and conclude that this exercise 
is influenced by geographical skew (preponderance of 
studies from the same surveillance sites) and hampered 
Number of 
estimates
Age 
(years)
Sex Region Study inclusion (excluding 
assay-based estimates)
HIV incidence events 
per 100 person-years 
(95% CI)
Dobra et al (2017),3 Justman et al (2017),6 Vandormael et al (2014),23 Tanser et al (2011),26 
Tanser et al (2013),27 Chimbindi et al (2018)29*, unpublished data from Iwuji et al (2018),32 
and unpublished data from Schaefer et al (2017)41 
9 15–19 Female SADC All 4∙22 (3∙61–4∙94)
Justman et al (2017)6 and unpublished data from Schaefer et al (2017)41 2 15–19 Female SADC Sensitivity analysis (excluding 
studies from uMkhanyakude)
1∙92 (0∙51–7∙15)
Dobra et al (2017),3 Vandormael et al (2014),23 Tanser et al (2011),26 Tanser et al (2013),27 
Chimbindi et al (2018),29* and Iwuji et al (2018)32
7 15–19 Female SADC Sensitivity analysis 
(uMkhanyakude studies only)
4∙88 (4∙64–5∙13)
Dobra et al (2017),3 Justman et al (2017),6 Vandormael et al (2014),23 Rosenberg et al 
(2013),25 Tanser et al (2011),26 Tanser et al (2013),27 Akullian et al (2017),28 unpublished data 
from Iwuji et al (2018),32 Chimbindi et al (2018),29* and unpublished data from Schaefer 
et al (2017)41† 
14 20–24 Female SADC All 4∙36 (3∙53–5∙39)
Justman et al (2017)6 and unpublished data from Schaefer et al (2017)41† 5 20–24 Female SADC Sensitivity analysis (excluding 
studies from uMkhanyakude)
1∙64 (0∙99–2∙73)
Dobra et al (2017),3 Vandormael et al (2014),23 Rosenberg et al (2013),25 Tanser et al (2011),26 
Tanser et al (2013),27 Akullian et al (2017),28 Chimbindi et al (2018),29* and unpublished data 
from Iwuji et al (2018)32
9 20–24 Female SADC Sensitivity analysis 
(uMkhanyakude studies only)
6∙86 (5∙93–7∙93)
Dobra et al (2017),3 Justman et al (2017),6 Vandormael et al (2014),23 Harling et al (2014),24 
Tanser et al (2011),26 Tanser et al (2013),27 Akullian et al (2017),28 unpublished data from 
Iwuji et al (2018),32 and unpublished data from Schaefer et al (2017)41
9 25–29 Female SADC All 4∙48 (3∙19–6∙31)
Justman et al (2017)6 and unpublished data from Schaefer et al (2017)41 2 25–29 Female SADC Sensitivity analysis (excluding 
studies from uMkhanyakude)
1∙52 (1∙20–1∙93)
Dobra et al (2017),3 Vandormael et al (2014),23 Harling et al (2014),24 Tanser et al (2011),26 
Tanser et al (2013),27 Akullian et al (2017),28 and unpublished data from Iwuji et al (2018)32
7 25–29 Female SADC Sensitivity analysis 
(uMkhanyakude studies only)
5∙71 (4∙07–8∙00)
Dobra et al (2017),3 Justman et al (2017),6 Vandormael et al (2014),23 Tanser et al (2013),27 
unpublished data from Iwuji et al (2018),32 and unpublished data from Schaefer et al 
(2017)41
6 15–19 Male SADC All 0∙69 (0∙52–0∙92)
Justman et al (2017)6 and unpublished data from Schaefer et al (2017)41 2 15–19 Male SADC Sensitivity analysis (excluding 
studies from uMkhanyakude)
0∙43 (0∙15–1∙25)
Dobra et al (2017),3 Vandormael et al (2014),23 Tanser et al (2013),27 and unpublished data 
from Iwuji et al (2018)32
4 15–19 Male SADC Sensitivity analysis 
(uMkhanyakude studies only)
0∙84 (0∙74–0∙97)
Dobra et al (2017),3 Justman et al (2017),6 Vandormael et al (2014),23 Rosenberg et al (2013),25 
Tanser et al (2013),27 Akullian et al (2017),28 Baisley et al (2018),30* unpublished data from 
Iwuji et al (2018),32 and unpublished data from Schaefer et al (2017)41† 
13 20–24 Male SADC All 1∙58 (1∙18–2∙10)
(Table 3 continues on next page)
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by heterogeneity. It also minimises the geographical, 
demographic, and epidemiological differences that must 
be understood to orient programming efforts. Going 
forward, tracking progress of such efforts will rely on 
greater comparability between studies, especially over 
time (more so than place), given the few trend analyses 
available to date.
It is possible that the studies reviewed here represent the 
highest estimates among young people—eg, through 
publication bias for which authors are more likely to report 
age breakdowns or in which journals are more likely to 
publish results with high numbers of sero conversions. 
When we requested disaggregations by age and sex, from 
18 authors who had published HIV incidence but not 
specifically for young women, the number of sero-
conversions in the unpublished reports were generally low 
and CIs often wide—possibly explaining why some of 
these estimates were not published previously. We received 
no data from eight of those studies and their omission 
might have distorted the final sample.
It is also possible that some published estimates 
appear higher than they might be for the youngest 
populations, because of methods that impute the timing 
of seroconversion from the midpoint (between last 
negative and first positive HIV test)—the method used 
by most analyses in the review. Among young people, the 
timing of infection is likely to be recent (ie, more recent 
than the midpoint), and use of the midpoint might 
inflate estimates at younger ages, especially if intervals 
between testing are long. Another probable influence 
is the need for parental consent among participants 
younger than 18 years; parental consent might impede 
participation of young people most likely to be home 
with parents (and less likely to be sexually active). Also, 
participation might be biased towards sexually active 
adolescents in studies where emancipated minors 
(eg, married or pregnant youth) have autonomy to 
consent. Finally, the most recent estimates will be 
overestimated if there is a delay in repeat testing among 
HIV-negative individuals, and the most current estimates 
might be corrected as more data become available.
There are also methodological reasons why the rates 
might be underestimated. Most published estimates are 
drawn from community surveillance areas, most of 
which are rural settings where incidence might be lower 
than in other parts of the country. Participation levels in 
sero-survey rounds were not always reported, and can 
be low because of research fatigue (at individual and 
population levels).76 Those who participate and consent 
to repeated HIV testing might be at lower risk than those 
Number of 
estimates
Age 
(years)
Sex Region Study inclusion (excluding 
assay-based estimates)
HIV incidence events 
per 100 person-years 
(95% CI)
(Continued from previous page)
Justman et al (2017)6 and unpublished data from Schaefer et al (2017)41† 5 20–24 Male SADC Sensitivity analysis (excluding 
studies from uMkhanyakude)
0∙56 (0∙29–1∙08)
Dobra et al (2017),3 Vandormael et al (2014),23 Rosenberg et al (2013),25 Tanser et al (2013),27 
Akullian et al (2017),28* Baisley et al (2018),30 and unpublished data from Iwuji et al (2018)32
8 20–24 Male SADC Sensitivity analysis 
(uMkhanyakude studies only)
2∙43 (1∙87–3∙15)
Dobra et al (2017),3 Justman et al (2017),6 Vandormael et al (2014),23 Tanser et al (2013),27 
Akullian et al (2017),28 Baisley et al (2018),30† unpublished data from Iwuji et al (2018),32 
and Feldblum et al (2014)48
9 25–29 Male SADC All 3∙34 (2∙58–4∙34)
Justman et al (2017)6 and unpublished data from Schaefer et al (2017)41 2 25–29 Male SADC Sensitivity analysis (excluding 
studies from uMkhanyakude)
1∙58 (0∙61–4∙13)
Dobra et al (2017),3 Vandormael et al (2014),23 Tanser et al (2013),27 Akullian et al (2017),28 
Baisley et al (2018),30† and unpublished data from Iwuji et al (2018)32
7 25–29 Male SADC Sensitivity analysis 
(uMkhanyakude studies only)
4∙19 (3∙48–5∙05)
Unpublished data from Ruzagira et al (2011),14 Borgdorff et al (2018),20 Biraro et al (2013),36 
unpublished data from Grabowski et al (2017),37* Santelli et al (2013),38 Santelli et al 
(2015)39* 
8 15–19 Female EAC All 0∙68 (0∙45–1∙04)
Unpublished data from Ruzagira et al (2011),14 Borgdorff et al (2018),20 Okiria et al (2014),35 
Biraro et al (2013),36 unpublished data from Grabowski et al (2017),37* Santelli et al (2013),38 
and Santelli et al (2015)39*  
9 20–24 Female EAC All 1∙23 (1∙01–1∙49)
Unpublished data from Ruzagira et al (2011),14 Borgdorff et al (2018),20 Okiria et al (2014),35 
Biraro et al (2013),36 and unpublished data from Grabowski et al (2017)37*
6 25–29 Female EAC All 1∙07 (0∙84–1∙36)
Unpublished data from Ruzagira et al (2011),14 Biraro et al (2013),20 unpublished data from 
Grabowski et al (2017),37* Santelli et al (2013),38 and Santelli et al (2015)39* 
7 15–19 Male EAC All 0∙21 (0∙12–0∙37)
Unpublished data from Ruzagira et al (2011),14 Borgdorff et al (2018),20 Okiria et al (2014),35 
Biraro et al (2013),36 unpublished data from Grabowski et al (2017),37* Santelli et al (2013),38 
and Santelli et al (2015)39*  
9 20–24 Male EAC All 0∙72 (0∙52–1∙02)
Unpublished data from Ruzagira et al (2011),14 Borgdorff et al (2018),20 Okiria et al (2014),35 
Biraro et al (2013),36 and unpublished data from Grabowski et al (2017)37*
6 25–29 Male EAC All 1∙32 (0∙93–1∙86)
EAC=East African Community. SADC=Southern African Development Community. *Two estimates from this study. †Four estimates from this study.
Table 3: Pooled estimates of HIV incidence from 19 general population studies by age, sex, and region
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who refuse or avoid participation and those who move in 
and out of the surveillance area or are unavailable (with 
mobility being associated with HIV risk in South Africa). 
Over time, as people learn their HIV status sooner 
after infection, those already diagnosed with HIV might 
have less incentive to participate in a sero-survey, which 
could skew the incidence estimates downward. Research 
from KwaZulu-Natal suggests participation bias can 
reduce the accuracy with which seroconversions can be 
dated, undermining validity, but does not introduce a 
systematic bias.76
The method of estimating HIV incidence might also 
underestimate rates—eg, with young people being less 
able to meet the need to have tested twice (they often 
miss a survey round because they are slightly too young 
to participate). Repeated testing is more likely to occur 
in sites with frequent opportunities to test and where 
participation is high. Where a substantial pro portion of 
young people have tested only once, because of age 
restrictions, it is desirable to impute a negative status at 
a suitable age to include their data. If young prevalent 
positive cases are discarded, the resulting estimates will 
be lower, since few young seroconverters will have had 
an earlier observation while HIV negative.
The results of this review will also be influenced by 
limitations of our search terms, strategy, and execution. 
For example, by not systematically searching conference 
abstracts or non-English language articles, we might 
have missed eligible estimates. Although accuracy and 
completeness of the estimates cannot be certain, and the 
results cannot be generalised or extrapolated beyond 
the study settings, this review shows that adolescent 
girls’ risk cannot be minimised. The pattern of rapidly 
increasing risk, from an earlier age in comparison with 
male peers, is consistent across settings and in the pooled 
analyses. The indirect benefits of ART are slow to yield 
reductions in the highest-prevalence settings, particularly 
where HIV testing and treatment among young adult 
men remain low. The sparse trend data available in this 
review indicate that absolute levels of incidence might 
well be declining, in various settings and populations, 
before investments targeting adolescent girls and young 
women such as DREAMS, but rates remain unacceptably 
high and the gender disparity during adolescence and 
early adulthood persists. Programmes such as DREAMS 
can tackle the underlying gender inequalities that drive 
dispropor tionately high risk among girls. Furthermore, 
where HIV incidence estimates are available in districts 
before DREAMS implementation—as is the case for 
several studies included in this review—such data are a 
valuable source with which to verify whether DREAMS 
initiates or accelerates declines in risk and achieves 
its important aims of reducing HIV infections among 
adolescent girls and young women in sub-Saharan Africa.
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